Multifocal intradural extramedullary ependymoma, MYCN amplified: illustrative case

Lisa B. E. Shields, MD,1 David A. Sun, MD, PhD,1 Hilary A. Highfield, MD, PhD,2 Renato V. LaRocca, MD,3 Aaron C. Spalding, MD, PhD,3 Kaylyn D. Sinicrope, MD,3 Yi Ping Zhang, MD,1 and Christopher B. Shields, MD1,4

1Norton Neuroscience Institute, 2CPA Laboratory, and 3Norton Cancer Institute, Norton Healthcare, Louisville, Kentucky; and 4Department of Neurological Surgery, University of Louisville School of Medicine, Louisville, Kentucky

BACKGROUND Ependymomas are the most frequent tumors of the adult spinal cord, representing 1.9% of all central nervous system tumors and 60% of spinal cord tumors. Spinal ependymomas are usually solitary, intramedullary lesions. While intradural extramedullary (IDEM) ependymomas are infrequent, multifocal IDEM ependymomas are exceptionally rare.

OBSERVATIONS The authors reported the first case in the literature of a patient diagnosed with multifocal IDEM ependymomas who was treated with tumor resection and brain and spinal radiotherapy. The patient presented with a 10-day history of bilateral leg numbness extending to the umbilicus and gait instability. Magnetic resonance imaging (MRI) studies revealed multiple enhancing nodular nodules throughout the entire spinal canal. Brain MRI revealed no abnormal lesions. A World Health Organization grade II ependymoma was confirmed histologically. At 31 months postoperatively, the patient remained clinically asymptomatic. Although cervical and thoracic MRI revealed stable intradural nodules and several areas of leptomeningeal enhancement, no malignant cells were seen in the cerebrospinal fluid (CSF). He underwent genetic testing to determine the appropriate chemotherapeutic agent if activation of the tumor should arise.

LESSONS Because complete resection of multifocal IDEM ependymomas is not feasible, continued monitoring with brain and spine MRI is warranted to detect potential tumor dissemination in the CSF.

https://thejns.org/doi/abs/10.3171/CASE22141

KEYWORDS neurosurgery; ependymoma; multifocal; intradural; extramedullary

Illustrative Case

History, Physical Examination, Radiological Imaging, and Laboratory Findings

A 45-year-old man (body mass index 32.92 kg/m²) reported a 10-day history of numbness of the lower extremities bilaterally that...
was described as a constant “prickling” sensation. The numbness initially extended from the bilateral knees distally and subsequently extended to the umbilicus. He also complained of gait instability. The patient attributed the numbness to buying new work boots. He had also sustained a fall from a ladder a few weeks prior to the initiation of his symptoms. On examination, the patient was able to feel pressure but no pain, vibration, or temperature sensation of the lower extremities bilaterally. Saddle anesthesia and numbness were noted in the inguinal region, and a sensory level was noted at T2. There was no weakness of the legs. The Achilles deep tendon reflex was absent on the right and 2+ on the left. The Babinski reflex was muted on the right and down on the left.

Thoracic magnetic resonance imaging (MRI) with and without gadolinium contrast demonstrated (1) a 1.2 × 1.5 × 3.5-cm enhancing mass filling the left side of the spinal canal extending from T1 to T3, resulting in marked displacement and compression of the spinal cord; (2) a 1.1 × 1.6 × 3-cm enhancing mass in the left side of the spinal canal at T11–12, causing moderate displacement and mild compression of the spinal cord; and (3) a 3.0-mm enhancing nodule within the posterior aspect of the spinal canal at T7 on the right (Fig. 1A–C). Lumbar MRI with and without gadolinium contrast revealed multiple enhancing nodular foci in the spinal canal: (1) an 8.0-mm enhancing nodule in the right posterior aspect of the spinal canal at the L3 level; (2) two 1.5-cm enhancing nodules filling most of the spinal canal at the L5–S1 level and extending superiority to L5; and (3) a 6.0-mm enhancing nodule within the posterior aspect of the spinal canal on the left at T12 (Fig. 1D–F). Cervical MRI with and without gadolinium contrast showed the aforementioned IDEM mass from T1 to the T2–3 level as well as a 2.0- to 3.0-mm IDEM mass at the posterior right side of the cord at C7. Brain MRI with and without gadolinium contrast revealed no pathological lesions.

CSF findings included protein >3,000 (12 to 60 mg/dL) and angiotensin-converting enzyme (ACE) 11 U/L (0 to 2.5 U/L). Serum ACE was 23 (9 to 67 U/L). The germ cell markers beta human chorionic gonadotropin and alpha fetoprotein were both negative (<1 U/L [0 to 3 U/L] and 1 ng/mL [0 to 1 ng/mL], respectively).

**Surgical Intervention**

A laminectomy of T1 and T2 was performed with resection of the IDEM mass (Fig. 2). A plane was delineated between the lesion and the cord, and multiple nerve rootlets were observed between the mass and cord. The lesion was debulked, and the capsule was resected from the cord. A region of arachnoid membrane clearly distinct from and caudal to the tumor was biopsied because of its abnormal appearance.

**Histopathological Findings**

Large areas of this ependymal tumor demonstrated a tanycytic phenotype with spindled elongate cells and suggestions of perivascular pseudorosettes (Fig. 3A and B), whereas other locations were hypercellular with classic ependymal architecture (Fig. 3C). Mitotic activity was rare, there were areas of necrosis, and microvascular proliferation was not identified. Tumor cells were strongly and
diffusely immunoreactive for glial fibrillary acidic protein (Fig. 3D), vimentin, and S-100. Epithelial membrane antigen labeled intracytoplasmic dot-like microlumina (Fig. 3E). The Ki-67 proliferation index was low overall, with labeling of up to 10% of tumor cell nuclei within the hypercellular nodules (Fig. 3F). The tumor showed MYCN copy number gain, and amplification of the HER-2 gene was not detected. Tumor cells were negative for somatostatin receptor 2A, SOX-10, STAT-6, and OLIG-2. A World Health Organization grade II ependymoma was confirmed. A separate biopsy site of arachnoid tissue also confirmed ependymoma infiltration.

**Adjuvant Therapy**

The patient received intensity-modulated radiation therapy rapid arc to the brain as well as the entire spinal axis (total dose...
3,060 cGy) in 17 fractions. He was also treated with an additional 5 fractions of focus radiotherapy to the areas of visible tumor (900 to 1,080 cGy). The patient did not receive chemotherapy.

Follow-Up
Within 2 weeks after surgical intervention, the patient attained significant improvement in both gait and sensation from T2 distally. At 18 months postoperatively, he reported mild cognitive decline presumably related to the cranial radiation. He denied any other neurological complaints. At 18 months after surgery, a brain MRI revealed no pathological masses. Cervical, thoracic, and lumbar MRI with and without gadolinium contrast demonstrated stable intradural nodules. Cervical and thoracic MRI showed new areas of leptomeningeal enhancement concerning for disease progression. CSF findings included protein 198 (12 to 60 mg/dL) with rare mononuclear cells and no malignant cells observed on microscopic examination. The elevated protein was attributed to the history of spinal surgery and stable spinal lesions.

The patient received genetic testing, which revealed a PIK3CA mutation (c. 1636C > A, p. Q546K, NM_006218, missense variant exon 9). PIK3CA encodes the catalytic subunit p100 alpha protein of the phosphatidylinositol 3-kinase (PI3K) enzyme.15 The p110 subunit is responsible for the enzyme’s phosphorylation activity and is involved in the PI3K-AKT-mTOR and the Ras-Raf-MEK-ERK pathways that mediate cellular growth and survival.16,17 Activating mutations, copy number gains, and overexpression of PIK3CA are associated with cancer progression. The PI3K pathway is one of the most frequently activated pathways in cancer.18 PI3Ks transduce signals from growth factors and cytokines, which results in the phosphorylation and activation of AKT, inducing changes in cell growth, proliferation, and apoptosis. In the analysis by Rogers and colleagues of the PI3K pathway using gene expression data and immunohistochemical analysis of phosphorylated AKT in pediatric ependymoma, they reported that the PI3K pathway could act as a biomarker to identify patients with a worse prognosis and those who could be treated with therapies targeted against the pathway.18 Butt and colleagues have also identified PIK3CA mutation patterns in a series of patients with ependymoma who received molecular profiling by next-generation sequencing.19

At 31 months postoperatively, the patient’s only complaints were increased fatigue and daytime somnolence. Cervical and thoracic MRI were stable without evidence of disease progression. The patient will continue to be monitored with brain and total spine MRI. If there is evidence of disease progression in the future, he may be a candidate for alpelisib off-label use due to his PI3CK mutation. He may also be enrolled in clinical trials or receive treatment with combination temozolomide and lапatinib for recurrent ependymoma.

Discussion
Several features commonly associated with IDEM ependymomas include diagnosis in the fifth decade, female predominance, thoracic spine location, encapsulated lesion without attachment to the central nervous system, and lack of other neoplastic processes within the brain or spinal cord.1,3,5,7,9–12,20 Patients often present with pain and progressive medullary compression. In the study by lunes and colleagues of 19 patients with IDEM, the time elapsed from symptom onset to diagnosis ranged between 1 month and 8 years, with most patients diagnosed in less than 1 year.7 MRI is the diagnostic gold standard, with gadolinium-contrast studies commonly demonstrating a homogenously enhanced, well-delineated tumor with a cystic, hemorrhagic, necrotic, and/or calcific component.12,21 Grade II (or “classic”) ependymomas comprise 55%–75% of spinal lesions and are characterized histologically by pseudorosettes (80%) and “true” or “ependymal” rosettes (10%).22 The tumor margins are usually well defined on gross and microscopic examination, with compression instead of invasion of the adjacent tissue. IDEM ependymomas often mimic schwannomas, meningiomas, or neurofibromas, which may delay their diagnosis.11–13

Although IDEM ependymomas are typically benign, they have been reported to recur, undergo anaplastic transformation, and seed in the CSF.3,4,6,9,12,21 Because IDEM ependymomas are usually solitary and isolated, complete resection is frequently performed and offers the best prognosis for a full recovery without recurrence. Adjuvant radiotherapy and chemotherapy remain controversial. However, the former has been shown to significantly improve overall survival, and the latter is usually reserved for salvage therapy if both surgery and radiotherapy fail.4,6,14,21

Only nine cases of multifocal IDEM ependymomas have been reported in the literature (Table 1).1–4,6,7,13,14 The mean age was 38 years (range, 26 to 53 years), and five (56%) patients were female. All patients had either neck and/or low back pain, paresthesia of the lower extremities, and/or gait abnormalities. MRI findings demonstrated IDEM ependymomas throughout the entire spine in most cases. Of the nine patients, two were grade I (myxopapillary), three were grade II, two were grade III (anaplastic), and one was a combination of grades II and III. All patients received at least one laminectomy, and six (67%) patients had adjuvant craniospinal or spinal radiotherapy. Only two (33%) patients were treated with chemotherapy, consisting of carboplatin in one case and temozolomide in one case. The follow-up duration ranged between 8 months and 10 years, with seven (78%) patients attaining excellent improvement of their symptoms after surgery, radiotherapy, and/or chemotherapy. One patient developed complete spinal cord syndrome 8 months after his second surgery and had an overall survival of 105 weeks. Another patient continued to experience sensory abnormalities of the legs 1 year postoperatively, which was attributed to postradia- myelopathy.

The mechanism associated with the development of multifocal IDEM ependymomas has been postulated to involve either drop metastasis or CSF migration cranially from a more distal location.3,4,6 Schurmans and colleagues surmised that the process in their case was either due to drop metastasis from the cervical IDEM ependymoma or that the lumbar IDEM ependymomas may have undergone anaplastic transformation with the cells migrating cranially in the CSF to form the cervical subdural and intracranial metastases.3 Vural and colleagues as well as Honda and colleagues speculated that the IDEM ependymomas may have disseminated to other spinal cord levels via the CSF or that the tumors may have occurred at multicentric foci.4,6 Vural and colleagues further investigated this concept by performing cytogenetic analysis to confirm the pathogenesis of tumor multiplicity.3 They determined that the tumors at different locations originated from the same primary tumor, specifically, the one at the cervicomedullary junction in their particular case. The tumor at this site was strongly enhancing radiologically, and the thoracic tumors were weakly enhancing, suggesting that poor vascularization of the latter may reflect an early stage of a disseminated tumor.
| Authors & Year                      | Age (yrs)/ Sex | Presenting Symptoms                                      | Tumor Site/WHO Grade | Treatment                                                                 | Outcome                                                                 |
|-----------------------------------|----------------|----------------------------------------------------------|----------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Schuurmans et al., 2006<sup>3</sup> | 29/F           | Progressive neck pain, sensory deficit, & weakness in both arms | C3–6, L4–S1/grade III | C3–6 laminectomy, C4–6 corpectomies, lumbar laminectomy; RT entire spinal cord; 2 yrs later resection of tumor in Sylvian fissure | Sensory abnormalities of legs 1 yr after spinal op, attributed to postradiation myelopathy |
| Vural et al., 2010<sup>4</sup>     | 45/F           | Progressive neck & back pain, difficulty in ambulation   | 4th ventricle-C2, T5–6, T8–9/grade II | Suboccipital craniectomy & C1 laminectomy, T5–6 & T8–9 laminectomies; no adjuvant therapy | Asymptomatic 3 yrs after op, although MRI showed multiple masses at T5, T7, T9, T12, L3, S1–2; will undergo op |
| Iunes et al., 2011<sup>7</sup>     | 32/M           | Partial medullary syndrome                               | Bulbomedullary junction, C2–3, T5–11, L2, L4, L5, sacrum/grade II | T7–9 laminectomy; chemo (4 cycles carboplatin); 10 mos later T9–10 laminectomy; RT (whole brain & neuraxis) | Complete spinal cord syndrome 8 mos after 2nd op; OS 105 wks |
| Landriel et al., 2012<sup>14</sup>| (1) 30/M (2) 32/M | (1) Progressive paresthesia & paresis in legs; urinary sphincter disturbances; gait instability; ataxia; chronic LBP (2) Paresthesia in rt leg | (1) C2–3, T2–T4–T5, T12–L1/grade I (2) C7, T2, T4, T5, T8, T10, T11, L1, L3, L5, S1, S2/grade I | (1) T1–3 laminectomy; radiotherapy (2) T9–10 laminectomy | (1) Good neurological outcome, no residual tumor on MRI at 10 yrs (2) Good neurological outcome, no residual tumor on MRI at 12 mos |
| Guarnieri et al., 2014<sup>2</sup> | 53/M           | Progressive lower leg hypoesthesia                        | Lower cervical, upper & lower thoracic (unspecified levels)/grade II | Lower thoracic laminectomy; 1 mo later lower cervical & upper thoracic laminectomy; chemo (4 cycles carboplatin) | Improved after 2nd op, able to stand on own & walk w/o assistance |
| Vats et al., 2015<sup>13</sup>     | 49/F           | Neck pain, spastic quadriaparesis                        | C1–2, C6–7, T4–L3/grade II | C5–7 laminectomy, T7–9 laminectomy; RT | Patient “doing well” at 11 mos postoperative |
| Chakravorty et al., 2017<sup>1</sup> | 47/F           | Gluteal, thigh, & groin pain; groin paresthesia          | >10 lesions in CMJ, cervical, thoracic, lumbar, sacral, cauda equina (unspecified levels)/grade III | Sacral laminectomy; 1 yr later T4–6 laminectomy; craniospinal RT | Asymptomatic 4 yrs after presentation |
| Honda et al., 2017<sup>6</sup>     | 26/F           | Difficulty walking due to progressive paresis, pain in trunk, leg numbness | Thoracic (7 lesions, unspecified levels)/both grades II & III | T3–4 laminectomy (resected 2 lesions upper thoracic); 5 wks later T5–10 laminectomy (resected 5 residual lesions); craniospinal RT; chemo (temozolomide) | Improved neurological condition & able to walk w/o support 3 yrs after 2nd op, no recurrence or dissemination on MRI |
| Present case                      | 45/M           | Numbness both legs to umbilicus, gait instability        | C7, T1–3, T7, T12, L3, L5–S1/grade II | T1–2 laminectomy; RT brain & entire spine | Improvement of gait & sensation T4 distally 2 wks after op, mild cognitive decline 18 mos after op attributed to cranial radiation, no tumor progression on cervical/thoracic MRI 31 mos postoperative |

Chemo = chemotherapy; CMJ = cervicomedullary junction; LBP = low back pain; op = surgery; OS = overall survival; RT = radiotherapy; WHO = World Health Organization.
Observations

The present case is the first to describe a patient diagnosed with a multifocal IDEM ependymoma who was treated with a tumor resection followed by radiation and received genetic testing to ascertain an appropriate chemotherapeutic agent. It has been reported that trauma in multifocal IDEM is known to cause hemorrhage, tumor rupture, and dissemination.\(^4\) It is unknown whether the fall from a ladder that our patient sustained weeks before the initiation of his symptoms may have contributed to the CSF dissemination of the ependymal cells, although this mechanism is possible. Because the patient had several IDEM ependymomas throughout his entire spine, the tumor resection was performed at the spinal level that localized to the patient’s neurological signs and symptoms, specifically, a T1–2 laminectomy. Although the brain MRI demonstrated no pathologic lesions, craniospinal radiation was performed in case there was a subclinical cerebral ependymoma. Intracranial ependymomas tend to be friable with a propensity to seed tumor cells in a cranial-caudal direction to the thoracic and lumbar subarachnoid space. Occult intracranial lesions could conceivably have been present in our case leading to these multiple drop metastases. We propose that the large lesion at T1–3 most likely had friable surface tumor cells that seeded caudally, causing the multifocal IDEM ependymomas.

While previous patients with multifocal IDEM ependymomas have been treated with carboplatin and temozolomide, our patient’s genetic testing revealed a PIK3CA mutation, enabling him to be a candidate for alpelisib. This personalized chemotherapy determination after testing for cancer gene alterations may prove invaluable when chemotherapy is deemed necessary. At 18 months postoperatively, the patient denied any neurological complaints apart from chemotherapy is deemed necessary. At 18 months postoperative, his only complaints were increased fatigue and daytime somnolence. Cervical and thoracic MRIs were stable without evidence of disease progression.

Lessons

Although a complete resection is the preferred treatment for a solitary IDEM ependymoma, it is not the most practical surgical option for multifocal IDEM ependymomas. Decompression of the lesion causing mass effect on the spinal cord is the ideal treatment, followed by adjunct radiotherapy and/or chemotherapy. Patients with multifocal IDEM ependymomas necessitate close monitoring with brain and total spine MRI studies to detect anaplastic transformation, recurrence, or CSF dissemination of these lesions.

Acknowledgments

We acknowledge Norton Healthcare for their continued support.

References

1. Chakravorty A, Frydenberg E, Shein TT, Ly J, Earls P, Steel T. Multifocal intradural extramedullary anaplastic ependymoma of the spine. J Spine Surg. 2017;3(4):727–731.
2. Guarnieri G, Tecame M, Izzo R, Zeccoli F, Genovese L, Muto M. Multisegmental diffuse intradural extramedullary ependymoma. An extremely rare case. Neuroradiol J. 2014;27(2):179–185.
3. Schuurmans M, Vanneste JA, Verstegen MJ, van Furth WR. Spinal extramedullary anaplastic ependymoma with spinal and intracranial metastases. J Neurooncol. 2006;79(1):57–59.
4. Vural M, Arslantas A, Ciftci E, Arta n S, Adapinar B. Multiple intradural-extramedullary ependymomas: proven dissemination by genetic analysis. J Neurosurg Spine. 2010;12(5):467–473.
5. Ali AS, Qureshi MS, Ahmed J, et al. Intradural extramedullary ependyma na at lumbar (L1-L4 level) spine: a suspicious case and literature review. J Clin Case Rep. 2015;S3:4.
6. Honda A, Izzuka Y, Hirato J, Kiyohara H, Izzuka H. Multiple intradural-extramedullary spinal ependymomas including tumors with different histological features. Eur Spine J. 2017;26(suppl 1):222–224.
7. Iunes EA, Stavale JN, de Cássia Caldas Pessoa R, et al. Multifocal intradural extramedullary ependymoma. Case report. J Neurosurg Spine. 2011;14(1):65–70.
8. Kaliperusal C, Suttner N, Herron B, Choudhari KA. Rare case of primary spinal ependymomatosis occurring in a 26-year-old man: a case report. J Med Case Reports. 2009;3:72.
9. Moriwaki T, Iwatsuki K, Ohnishi Y, Umegaki M, Ishihara M, Yoshi mine T. Intradural extramedullary spinal ependymoma: a case report of malignant transformation occurring. Asian Spine J. 2013;7(2):139–142.
10. Benzamgout M, Boujrafa S, Ouali N, et al. Intradural extramedullary ependymoma: is there constantly a hormonal relationship? Surg Neurol. 2008;70(5):536–538.
11. Duffau H, Gazzaz M, Kujas M, Fohanno D. Primary intradural extramedullary ependymoma: case report and review of the literature. Spine (Phila Pa 1976). 2000;25(15):1993–1995.
12. Son DW, Song S, Han IH, Choi BK. Primary extramedullary ependymoma of the cervical spine: case report and review of the literature. J Korean Neurosurg Soc. 2011;50(1):57–59.
13. Vats A, Ramdasi R, Zaveri G, Pandya S. Multicentric intradural extramedullary ependymoma: report of a rare case. J Craniovertebr Junction Spine. 2015;6(3):134–136.
14. Landriel F, Ajler P, Tedesco N, Bendersky D, Vecchi E. Multicentric extramedullary myxopapillary ependymomas: two case reports and literature review. Surg Neurol Int. 2012;3:102.
15. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455–459.
16. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2(3):261–274.
17. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012;4(9):a011189.
18. Rogers HA, Mayne C, Chapman RJ, Kilday JP, Coyle B, Grundy RG. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. Clin Cancer Res. 2013;19(23):6450–6460.
19. Butt E, Alyami S, Nageeti T, et al. Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing. F1000 Res. 2019;8:613.
20. Weinstein GM, Arunk K, Krzyzanski J, Lanfranchi M, Gupta GK, Bedi H. Spinal intradural, extramedullary ependymoma with astrocytoma component: a case report and review of the literature. Case Rep Pathol. 2016;2016:3534791.
21. Celano E, Salehani A, Malcolm JG, Reinertsen E, Hadjipanayis CG. Spinal cord ependymoma: a review of the literature and case series of ten patients. J Neurooncol. 2016;128(3):377–386.

Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions

Conception and design: CB Shields, LBE Shields, Sun, Spalding, Sinicrope. Acquisition of data: CB Shields, LBE Shields, Highfield, LaRocca, Sun. Analysis and interpretation of data: CB Shields, LBE Shields, Highfield, Spalding, Sun. Drafting the article: LBE Shields. Critically revising the article: all authors. Reviewed submitted version of
manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: CB Shields, LBE Shields. Administrative/technical/material support: CB Shields, LBE Shields. Study supervision: CB Shields.

**Correspondence**
Christopher B. Shields: Norton Neuroscience Institute, Norton Healthcare, Louisville, KY. cbshields1@gmail.com.